Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:collaborates_with |
Research Institutions
|
| gptkbp:develops |
Therapeutics
|
| gptkbp:employs |
gptkb:physicist
|
| gptkbp:focuses_on |
gptkb:Cancer_Immunotherapy
|
| gptkbp:founded |
gptkb:2014
|
| gptkbp:has_product |
ADU-741
ADU-CL-24 |
| gptkbp:has_website |
www.adurobiotech.com.au
|
| gptkbp:headquarters |
gptkb:Australia
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aduro Biotech Australia
|
| gptkbp:is_involved_in |
Biopharmaceutical Development
|
| gptkbp:is_known_for |
Innovative Cancer Treatments
|
| gptkbp:is_part_of |
gptkb:legal_case
|
| gptkbp:part_of |
gptkb:Aduro_Biotech,_Inc.
|
| gptkbp:partnerships |
Pharmaceutical Companies
|
| gptkbp:receives_funding_from |
Venture Capital
|
| gptkbp:research_focus |
Immune Modulation
Oncolytic Virus Therapy |
| gptkbp:bfsParent |
gptkb:Aduro_Biotech,_Inc.
|
| gptkbp:bfsLayer |
5
|